SB497 - Health Insurance and Maryland Medical Assistance Program - Coverage - Opioid Reversal Drugs and Products
Maryland - 2024 Regular Session
Introduced byDawn D. Gile
Last updated 8 months ago
1 Co-Sponsor
Requiring the Maryland Medical Assistance Program and certain insurers, nonprofit health service plans, and health maintenance organizations to cover nonprescription naloxone hydrochloride and any other drug or product that is approved by the federal Food and Drug Administration for the complete or partial reversal of an opioid overdose without imposing a copayment or coinsurance requirement that exceeds $10 per package.
STATUS
Introduced
Verifications Required
You must be a verified voter to do that.
No Thanks, I'll do it later
Verify your identity now